Cargando…

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline

BACKGROUND: Carcinoma of the esophagus is an aggressive malignancy with an increasing incidence. Its virulence, in terms of symptoms and mortality, justifies a continued search for optimal therapy. A clinical practice guideline was developed based on a systematic review investigating neoadjuvant or...

Descripción completa

Detalles Bibliográficos
Autores principales: Malthaner, Richard A, Wong, Rebecca KS, Rumble, R Bryan, Zuraw, Lisa
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC522817/
https://www.ncbi.nlm.nih.gov/pubmed/15447791
http://dx.doi.org/10.1186/1471-2407-4-67
_version_ 1782121853698965504
author Malthaner, Richard A
Wong, Rebecca KS
Rumble, R Bryan
Zuraw, Lisa
author_facet Malthaner, Richard A
Wong, Rebecca KS
Rumble, R Bryan
Zuraw, Lisa
author_sort Malthaner, Richard A
collection PubMed
description BACKGROUND: Carcinoma of the esophagus is an aggressive malignancy with an increasing incidence. Its virulence, in terms of symptoms and mortality, justifies a continued search for optimal therapy. A clinical practice guideline was developed based on a systematic review investigating neoadjuvant or adjuvant therapy on resectable thoracic esophageal cancer. METHODS: A systematic review with meta-analysis was developed and clinical recommendations were drafted. External review of the practice guideline report by practitioners in Ontario, Canada was obtained through a mailed survey, and incorporated. Final approval of the practice guideline was obtained from the Practice Guidelines Coordinating Committee. RESULTS: The systematic review was developed and recommendations were drafted, and the report was mailed to Ontario practitioners for external review. Ninety percent of respondents agreed with both the evidence summary and the draft recommendations, while only 69% approved of the draft recommendations as a practice guideline. Based on the external review, a revised document was created. The revised practice guideline was submitted to the Practice Guidelines Coordinating Committee for review. All 11 members of the PGCC returned ballots. Eight PGCC members approved the practice guideline report as written and three members approved the guideline conditional on specific concerns being addressed. After these recommended changes were made, the final practice guideline report was approved. CONCLUSION: In consideration of the systematic review, external review, and subsequent Practice Guidelines Coordinating Committee revision suggestions, and final approval, the Gastrointestinal Cancer Disease Site Group recommends the following: For adult patients with resectable thoracic esophageal cancer for whom surgery is considered appropriate, surgery alone (i.e., without neoadjuvant or adjuvant therapy) is recommended as the standard practice.
format Text
id pubmed-522817
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5228172004-10-17 Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline Malthaner, Richard A Wong, Rebecca KS Rumble, R Bryan Zuraw, Lisa BMC Cancer Research Article BACKGROUND: Carcinoma of the esophagus is an aggressive malignancy with an increasing incidence. Its virulence, in terms of symptoms and mortality, justifies a continued search for optimal therapy. A clinical practice guideline was developed based on a systematic review investigating neoadjuvant or adjuvant therapy on resectable thoracic esophageal cancer. METHODS: A systematic review with meta-analysis was developed and clinical recommendations were drafted. External review of the practice guideline report by practitioners in Ontario, Canada was obtained through a mailed survey, and incorporated. Final approval of the practice guideline was obtained from the Practice Guidelines Coordinating Committee. RESULTS: The systematic review was developed and recommendations were drafted, and the report was mailed to Ontario practitioners for external review. Ninety percent of respondents agreed with both the evidence summary and the draft recommendations, while only 69% approved of the draft recommendations as a practice guideline. Based on the external review, a revised document was created. The revised practice guideline was submitted to the Practice Guidelines Coordinating Committee for review. All 11 members of the PGCC returned ballots. Eight PGCC members approved the practice guideline report as written and three members approved the guideline conditional on specific concerns being addressed. After these recommended changes were made, the final practice guideline report was approved. CONCLUSION: In consideration of the systematic review, external review, and subsequent Practice Guidelines Coordinating Committee revision suggestions, and final approval, the Gastrointestinal Cancer Disease Site Group recommends the following: For adult patients with resectable thoracic esophageal cancer for whom surgery is considered appropriate, surgery alone (i.e., without neoadjuvant or adjuvant therapy) is recommended as the standard practice. BioMed Central 2004-09-24 /pmc/articles/PMC522817/ /pubmed/15447791 http://dx.doi.org/10.1186/1471-2407-4-67 Text en Copyright © 2004 Malthaner et al; licensee BioMed Central Ltd.
spellingShingle Research Article
Malthaner, Richard A
Wong, Rebecca KS
Rumble, R Bryan
Zuraw, Lisa
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
title Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
title_full Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
title_fullStr Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
title_full_unstemmed Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
title_short Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
title_sort neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC522817/
https://www.ncbi.nlm.nih.gov/pubmed/15447791
http://dx.doi.org/10.1186/1471-2407-4-67
work_keys_str_mv AT malthanerricharda neoadjuvantoradjuvanttherapyforresectableesophagealcanceraclinicalpracticeguideline
AT wongrebeccaks neoadjuvantoradjuvanttherapyforresectableesophagealcanceraclinicalpracticeguideline
AT rumblerbryan neoadjuvantoradjuvanttherapyforresectableesophagealcanceraclinicalpracticeguideline
AT zurawlisa neoadjuvantoradjuvanttherapyforresectableesophagealcanceraclinicalpracticeguideline
AT neoadjuvantoradjuvanttherapyforresectableesophagealcanceraclinicalpracticeguideline